Skip to main content
Log in

The sleepiness and cataplexy associated with narcolepsy are generally controllable with treatment

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II

References

  1. Chakravorty SS, Rye DB. Narcolepsy in the older adult: epidemiology, diagnosis and management. Drugs Aging 2003; 20(5): 361–76

    Article  PubMed  Google Scholar 

  2. Mitler MM, Hayduk R. Benefits and risks of pharmacotherapy for narcolepsy. Drug Saf 2002; 25(11): 791–809

    Article  PubMed  CAS  Google Scholar 

  3. Ohayon M, Zulley J, Guilleminault C, et al. Prevalence and pathologic associations of sleep paralysis in the general population. Neurology 1999; 52: 1194–200

    Article  PubMed  CAS  Google Scholar 

  4. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50 Suppl. 1: S16–22

    Article  PubMed  CAS  Google Scholar 

  5. Moscovitch A, Partinen M, Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy’s borderland. Neurology 1993; 43: 55–60

    Article  PubMed  CAS  Google Scholar 

  6. Wake up! Treatment for childhood narcolepsy can prevent the development of serious social or academic problems. Drugs Ther Perspect 2001; 17(6): 5–8

    Article  Google Scholar 

  7. Hussain A, Qadiri M, Rees P, et al. An unusual cause of falls in an elderly patient. Int J Clin Pract 1999; 53(5): 399–400

    PubMed  CAS  Google Scholar 

  8. Littner M, Johnson SF, McCall WV, et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Standards of Practice Committee. Sleep 2001 Jun 15; 24(4): 451–66

    PubMed  CAS  Google Scholar 

  9. Physicians’ desk reference. 58th ed. Montvale (NJ): Thomson PPR, 2004

  10. British National Formulary. No. 47. London: The Pharmaceutical Press, 2004 Mar

  11. Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep 1994; 17: S107–12

    PubMed  CAS  Google Scholar 

  12. Broughton R, Fleming J, George C, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997; 49(2): 444–51

    Article  PubMed  CAS  Google Scholar 

  13. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998; 43: 88–97

    Article  Google Scholar 

  14. Guilleminault C, Pelayo R. Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up. Paediatr Drugs 2000; 2(1): 1–9

    PubMed  CAS  Google Scholar 

  15. Larrosa O, de la Llave Y, Bario S, et al. Stimulant and anticat-aplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 2001; 24: 282–5

    PubMed  CAS  Google Scholar 

  16. Hublin C, Partinen M, Heinonen E, et al. Selegiline in the treatment of narcolepsy. Neurology 1994; 44: 2095–101

    Article  PubMed  CAS  Google Scholar 

  17. Mayer G, Meier K, Hephata K. Selegeline hydrochloride treatment in narcolepsy: a double-blind placebo-controlled study. Clin Neuropharmacol 1995; 18(4): 306–19

    Article  PubMed  CAS  Google Scholar 

  18. Rye D, Dihenia B, Bliwise D. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Depress Anxiety 1998; 7: 92–5

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The sleepiness and cataplexy associated with narcolepsy are generally controllable with treatment. Drugs Ther. Perspect 20, 15–18 (2004). https://doi.org/10.2165/00042310-200420070-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200420070-00005

Navigation